Top Page
SanBio Co
(OTC:4592)
SanBio Co (4592) vs. iShares MSCI Japan ETF (EWJ)
SanBio Co Business Overview & Revenue Model
SanBio Co Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -14.50M | -24.61M | -132.47M | -74.45M |
| EBITDA | -3.51B | -4.53B | -4.62B | -4.37B | -5.73B |
| Net Income | -2.88B | -2.64B | -5.56B | -4.68B | -3.39B |
Balance Sheet | |||||
| Total Assets | 3.45B | 5.05B | 7.05B | 5.51B | 13.34B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 4.45B | 6.73B | 4.56B | 12.48B |
| Total Debt | 397.00M | 665.00M | 933.00M | 2.52B | 4.00B |
| Total Liabilities | 1.68B | 2.25B | 2.62B | 3.48B | 4.99B |
| Stockholders Equity | 1.76B | 2.79B | 4.43B | 2.04B | 8.35B |
Cash Flow | |||||
| Free Cash Flow | -3.61B | -4.82B | -7.44B | -6.60B | -5.35B |
| Operating Cash Flow | -3.62B | -4.78B | -7.43B | -6.55B | -5.22B |
| Investing Cash Flow | -4.27M | -19.03M | -10.10M | -66.26M | 4.18B |
| Financing Cash Flow | 2.09B | 2.38B | 9.45B | -1.50B | -56.57M |
SanBio Co Technical Analysis
SanBio Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
48 Neutral | $151.38B | ― | -197.82% | ― | ― | -3.32% | |
| ― | €887.35M | 104.70 | -2.52% | ― | ― | ― | |
| ― | $1.50B | 15.77 | 29.98% | ― | ― | ― | |
| ― | $518.59M | ― | -3.36% | ― | ― | ― | |
61 Neutral | ¥99.22B | 95.31 | 2.06% | 3.53% | -29.66% | ||
47 Neutral | ¥18.89B | ― | ― | -100.00% | -1079.89% |
SanBio Co Corporate Events
SanBio Co., Ltd. announced the successful completion of the third commercial production run for AKUUGO® Suspension for Intracranial Implantation, a regenerative medicine product designed to aid brain nerve tissue repair. The yield results met expectations, and pending compliance confirmation, the company plans to file for product approval, with shipments projected to begin in the second quarter of the fiscal year ending January 31, 2026. This development is expected to have minimal impact on the current fiscal year’s financial performance.
SanBio Co., Ltd. announced a strategic financial restructuring aimed at reducing its tax burden and achieving a healthier financial platform. The company plans to reduce its stated capital and capital reserves by over 3.5 billion yen to cover a deficit in retained earnings, ensuring no impact on shareholders or net assets per share. This move is intended to facilitate more agile capital policies, including potential shareholder returns, without affecting the company’s business performance.
SanBio Co., Ltd. announced a deviation from its consolidated earnings forecast for the fiscal year ending January 31, 2025, with actual results showing a larger-than-expected ordinary loss. This was primarily due to foreign exchange gains on foreign currency loans and stock issuance expenses. The net loss attributable to owners was also higher than projected due to gains on reversal of share subscription rights and deferred tax liabilities. These results may impact the company’s financial stability and investor confidence.
SanBio Co., Ltd. reported financial results for the fiscal year ending January 31, 2025, highlighting a foreign exchange gain of 622 million yen and a foreign currency translation adjustment of negative 642 million yen. The company also recorded 113 million yen in stock issuance expenses, a 9 million yen gain from the reversal of share acquisition rights, and deferred income taxes of negative 128 million yen, reflecting its complex financial activities and their impact on earnings performance.
SanBio Co. reported its consolidated financial results for the fiscal year ending January 31, 2025, showing a reduction in net losses compared to the previous year. Despite ongoing financial challenges, including negative operating and ordinary income, the company remains committed to its strategic goals, with no significant changes in accounting policies or consolidation scope.
SanBio Co., Ltd. announced the publication of interim analysis results from a Phase 2 clinical trial of their SB623 product in the journal Neurotrauma Reports. The study examined the efficacy of stem cell transplantation in TBI patients, highlighting how the implantation site’s proximity to injury affects treatment outcomes. The results underscore the importance of tailoring surgical approaches in regenerative medicine, as advised by Japan’s Ministry of Health, Labour and Welfare, to enhance therapeutic outcomes.
SanBio Co., Ltd. announced the successful completion of their second commercial production run for AKUUGO Suspension, which is designed for intracranial implantation in regenerative medicine. The run met all required specifications, and the company plans to file a partial change application, maintaining their timeline for shipment in the second quarter of the fiscal year ending January 2026.
SanBio Co., Ltd. has entered into a contract manufacturing agreement with JCR Pharmaceuticals for the trial production of AKUUGO® Suspension for Intracranial Implantation. This collaboration aims to explore future manufacturing opportunities to ensure stable production and diversify supply, particularly as SanBio seeks market expansion into the US and additional indications such as ischemic stroke. The agreement is expected to have minimal impact on the current fiscal year’s financial performance.